Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mani, Inc. (7730.T)
JPY1,752.00
+10.00 (+0.57%)
JP JPX Healthcare Medical - Specialties
Address
8-3 Kiyohara Industrial Park 321-3231
Utsunomiya, JP
Utsunomiya, JP
CEO
Masaya Watanabe
Website
mani.co.jp
IPO
2010-02-22
ISIN JP3869920003
Description
Mani, Inc. engages in the manufacture and supply of surgical and dental instruments in Japan, Asia, Europe, North America, and internationally. The company operates through three segments: Surgical Products, Eyeless Needle Products, and Dental Products. The company offers surgical instruments, such as maniplers, vessel knives, ENT knives, and stainless wire needles; and ophthalmic instruments, including ophthalmic sutures and knives, and trocar kits for vitrectomy. It also provides surgical eyeless, eyed, taper point, cutting, ophthalmic needles; and dental instruments, such as endodontic instruments, endodontic rotary instruments, root canal obturation, diamond and carbide burs, finishing and polishing instruments, sutures and surgical needles, endodontic micro-accessories, and endodontic accessories. Mani, Inc. was founded in 1956 and is headquartered in Utsunomiya, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY1,752.00
+10.00 (+0.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
333.2K
Beta
0.38
Float Shares
65.43M
Free Float %
66.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.10% | -0.34% | +2.52% | +4.53% | +19.59% | +19.10% | +45.27% | +7.29% | -27.27% | +199.32% | +365.82% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,752.00
DCF (Unlevered)
1,418.20
-19.1%
DCF (Levered)
1,454.76
-17.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
57% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 3 | -2 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
23.97
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%+5.1% Q1'26: +15.7% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-26.1% Q1'26: +49.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+11.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+23.7% ★ Q1'26: +34.3% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+13.3% ★ Q1'26: +22.9% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.0% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.01× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Aug 2015 actual |
Aug 2016 actual |
Aug 2017 actual |
Aug 2018 actual |
Aug 2019 actual |
Aug 2020 actual |
Aug 2021 actual |
Aug 2022 actual |
Aug 2023 actual |
Aug 2024 actual |
Aug 2025 actual |
Aug 2026 9 Rev. Ana. 9 EPS Ana. |
Aug 2027 8 Rev. Ana. 8 EPS Ana. |
Aug 2028 8 Rev. Ana. 8 EPS Ana. |
Aug 2029 7 Rev. Ana. 6 EPS Ana. |
Aug 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.83B
est: 13.70B (+1.0%)
|
16.56B
est: 16.47B (+0.5%)
|
17.17B
est: 16.67B (+3.0%)
|
20.10B
est: 20.19B (-0.4%)
|
18.33B
est: 18.73B (-2.2%)
|
15.20B
est: 15.16B (+0.3%)
|
17.19B
est: 17.43B (-1.4%)
|
20.42B
est: 19.87B (+2.8%)
|
24.49B
est: 23.70B (+3.3%)
|
28.51B
est: 28.31B (+0.7%)
|
29.97B
est: 29.56B (+1.4%)
|
33.31B
32.60B – 34.10B
+12.7% YoY
|
36.26B
35.22B – 37.38B
+8.9% YoY
|
39.35B
39.28B – 39.41B
+8.5% YoY
|
41.03B
39.99B – 42.15B
+4.3% YoY
|
43.95B
42.85B – 45.15B
+7.1% YoY
|
| EBITDA |
5.25B
est: 5.55B (-5.3%)
|
5.26B
est: 6.67B (-21.1%)
|
5.95B
est: 6.75B (-11.8%)
|
6.67B
est: 8.18B (-18.5%)
|
9.76B
est: 7.59B (+28.7%)
|
6.26B
est: 6.14B (+2.0%)
|
7.55B
est: 7.06B (+6.9%)
|
9.17B
est: 8.05B (+13.9%)
|
9.94B
est: 9.60B (+3.6%)
|
10.70B
est: 11.26B (-5.0%)
|
9.56B
est: 11.76B (-18.7%)
|
13.25B
12.96B – 13.56B
+12.7% YoY
|
14.42B
14.01B – 14.86B
+8.9% YoY
|
15.65B
15.62B – 15.67B
+8.5% YoY
|
16.31B
15.90B – 16.76B
+4.3% YoY
|
17.48B
17.04B – 17.96B
+7.1% YoY
|
| EBIT |
4.37B
est: 4.41B (-1.0%)
|
4.05B
est: 5.30B (-23.5%)
|
4.65B
est: 5.37B (-13.4%)
|
5.19B
est: 6.50B (-20.1%)
|
8.40B
est: 6.03B (+39.3%)
|
4.85B
est: 4.88B (-0.6%)
|
6.00B
est: 5.61B (+7.0%)
|
7.42B
est: 6.40B (+16.0%)
|
8.02B
est: 7.63B (+5.1%)
|
8.43B
est: 8.91B (-5.3%)
|
7.09B
est: 9.30B (-23.8%)
|
10.48B
10.26B – 10.73B
+12.7% YoY
|
11.41B
11.08B – 11.76B
+8.9% YoY
|
12.38B
12.36B – 12.40B
+8.5% YoY
|
12.90B
12.58B – 13.26B
+4.3% YoY
|
13.82B
13.48B – 14.20B
+7.1% YoY
|
| Net Income |
2.93B
est: 2.85B (+2.9%)
|
3.01B
est: 2.79B (+7.7%)
|
3.32B
est: 3.18B (+4.2%)
|
3.77B
est: 3.55B (+6.1%)
|
6.10B
est: 6.08B (+0.4%)
|
3.33B
est: 3.51B (-5.2%)
|
4.29B
est: 4.22B (+1.6%)
|
5.29B
est: 4.74B (+11.6%)
|
5.95B
est: 5.18B (+15.0%)
|
6.29B
est: 6.31B (-0.4%)
|
4.64B
est: 5.47B (-15.0%)
|
7.19B
6.57B – 8.03B
+31.5% YoY
|
7.97B
7.63B – 8.60B
+10.9% YoY
|
8.79B
8.25B – 9.69B
+10.3% YoY
|
8.96B
8.67B – 9.28B
+1.9% YoY
|
9.65B
9.34B – 10.00B
+7.7% YoY
|
| SGA |
2.77B
est: 3.52B (-21.5%)
|
3.98B
est: 4.24B (-5.9%)
|
4.26B
est: 4.29B (-0.7%)
|
4.99B
est: 5.19B (-3.9%)
|
3.85B
est: 4.82B (-20.0%)
|
3.70B
est: 3.90B (-5.2%)
|
3.89B
est: 4.48B (-13.3%)
|
4.53B
est: 5.11B (-11.3%)
|
5.65B
est: 6.10B (-7.3%)
|
6.74B
est: 7.28B (-7.5%)
|
11.12B
est: 7.61B (+46.3%)
|
8.57B
8.39B – 8.77B
+12.7% YoY
|
9.33B
9.06B – 9.62B
+8.9% YoY
|
10.12B
10.11B – 10.14B
+8.5% YoY
|
10.55B
10.29B – 10.84B
+4.3% YoY
|
11.31B
11.02B – 11.62B
+7.1% YoY
|
| EPS |
29.53
est: 28.94 (+2.0%)
|
30.36
est: 28.34 (+7.1%)
|
33.68
est: 32.29 (+4.3%)
|
38.31
est: 36.08 (+6.2%)
|
61.99
est: 61.69 (+0.5%)
|
33.83
est: 35.65 (-5.1%)
|
43.60
est: 42.88 (+1.7%)
|
53.75
est: 48.14 (+11.6%)
|
60.45
est: 52.62 (+14.9%)
|
63.82
est: 63.54 (+0.4%)
|
47.14
est: 55.96 (-15.8%)
|
74.29
66.69 – 81.56
+32.7% YoY
|
81.14
77.43 – 87.26
+9.2% YoY
|
89.82
83.73 – 98.38
+10.7% YoY
|
91.00
88.03 – 94.24
+1.3% YoY
|
98.00
94.80 – 101.49
+7.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.35B
OE per share TTM
13.69
Owner's Yield
0.78%
Maintenance CapEx ratio
45.53%
Maint CapEx / Avg PPE
75.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.71M
Shares Outstanding
98.50M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hideshi Fukumoto | SMEO, Div Head of Monozukuri Div & Dept.,Head of Research Dept., Head of Manu. Div. & Global Chief Technology Officer | — | male |
| Kazuo Takahashi | MD & Director | — | male |
| Kentaro Inatomi | Administrative Officer & Department Head of Global Opera. Department | — | male |
| Masahiko Saito | Executive Chairman, GM of Technical Fellow & Head of Quality Assurance Department | — | male |
| Masaya Watanabe | Chief Executive Officer, President, Representative Executive Officer & Director | — | male |
| Shuichi Kurita | Sr Mng Executive Offcr, Hd of Bus Div, Ofc & Head of Glbl Sales Dept | — | — |
| Takayuki Yamamoto | Managing Executive Officer, CRO, Head of Corporate Planning Office & Chief Financial Officer | — | — |
| Tomomi Kosaka | Managing Exec Offcr Asst Div Head of Monozukuri Division & Dept Head of Manufacturing Dept. | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7730.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
